Agios Pharmaceuticals, Inc.
Every calculator, already run for AGIO
Open the full toolkit →You have the numbers on AGIO. Get the argument.
A written report on which of these readings actually decide the outcome for Agios Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering AGIOAnalyst Price Target Disagreement for Agios Pharmaceuticals, Inc.
Wall Street's bull case implies +118% from the current price; the bear case implies -4%. A 123% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AGIO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator…
AGIO — frequently asked
Is AGIO a buy right now?
Wall Street's consensus rating on Agios Pharmaceuticals, Inc. is Buy across 10 analysts, with a mean price target of $46.25 (+38% vs. the current $33.42). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is AGIO's next earnings date?
Agios Pharmaceuticals, Inc. is next scheduled to report earnings around Oct 29, 2026. A full AGIO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Agios Pharmaceuticals, Inc.?
Analysts covering Agios Pharmaceuticals, Inc. (AGIO) range from a bear-case target of $32.00 to a bull-case high of $73.00, with a mean consensus target of $46.25 across 8 analysts. The spread of $41.00 (123% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Agios Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Agios Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AGIO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Agios Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.